We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$3.17M
AUM Growth
+$561K
Cap. Flow
+$147M
Cap. Flow %
4,647.33%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
2
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M
3
ACGN
Aceragen Inc
ACGN
+$2.48M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$2.06M
5
PRQR icon
ProQR Therapeutics
PRQR
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 9.16%
2 Energy 0.42%
3 Industrials 0.14%
4 Consumer Staples 0.11%
5 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCRX
101
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.74K 0.09%
+429,945
New +$2.52M
PGEN icon
102
PUT
Precigen
PGEN
$1.97B
$2.72K 0.09%
1,033
-13
-1% -$285
ASPX
103
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$2.62K 0.08%
50,000
-70,000
-58% -$2.06M
AKTX
104
Akari Therapeutics
AKTX
$14.8M
$2.59K 0.08%
67
-41
-38% -$1.79M
TTOO
105
DELISTED
T2 Biosystems, Inc
TTOO
$2.57K 0.08%
27
+6
+29% +$495K
LITS
106
Lite Strategy Inc
LITS
$33M
$2.56K 0.08%
30,000
+16,814
+128% +$2.21M
RGLS
107
CALL
DELISTED
Regulus Therapeutics
RGLS
$2.5K 0.08%
+92
New +$164K
TXMD icon
108
TherapeuticsMD
TXMD
$23.8M
$2.45K 0.08%
+10,997
New +$2.27M
DRNA
109
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.4K 0.08%
145,919
-114,081
-44% -$1.32M
TEVA icon
110
CALL
Teva Pharmaceuticals
TEVA
$36.9B
$2.39K 0.08%
416
-628
-60% -$35K
TRUP icon
111
Trupanion
TRUP
$1.11B
$2.39K 0.08%
345,205
+110,205
+47% +$723K
OCUL icon
112
Ocular Therapeutix
OCUL
$1.85B
$2.33K 0.07%
98,951
-198,156
-67% -$3.33M
CYH icon
113
Community Health Systems
CYH
$393M
$2.32K 0.07%
+52,063
New +$2.23M
CRDC
114
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$2.2K 0.07%
314,666
+212,752
+209% +$1.75M
SCTL
115
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$2.2K 0.07%
856,137
+546,722
+177% +$1.38M
ALBO
116
DELISTED
Albireo Pharma Inc
ALBO
$2.15K 0.07%
53,838
+4,078
+8% +$179K
RXDX
117
DELISTED
Ignyta, Inc.
RXDX
$2.13K 0.07%
311,191
+81,490
+35% +$554K
NPSP
118
CALL
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$2.13K 0.07%
594
+94
+19% +$2.81K
NVAX icon
119
CALL
Novavax
NVAX
$1.21B
$2.06K 0.07%
+174
New +$18.2K
FOLD
120
DELISTED
Amicus Therapeutics
FOLD
$2.05K 0.06%
+246,697
New +$1.69M
SHPG
121
DELISTED
Shire pic
SHPG
$2.05K 0.06%
9,652
-303
-3% -$64.3K
INCY icon
122
PUT
Incyte
INCY
$26B
$2K 0.06%
+273
New +$17.8K
TSRO
123
CALL
DELISTED
TESARO, Inc.
TSRO
$1.99K 0.06%
534
-1,073
-67% -$33.1K
SVRA icon
124
Savara
SVRA
$1.09B
$1.98K 0.06%
+50,568
New +$1.77M
XOMA
125
CALL
DELISTED
Xoma
XOMA
$1.98K 0.06%
275
+120
+77% +$10.3K
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17M, up 22% from $2.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $147M of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1K.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, up from 6.3% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1K.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Aceragen Inc in Q4 2014, selling an estimated $2.48M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17M portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17M.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.